Log in
Enquire now
‌

GATEWAY BIOTECHNOLOGY, INC. STTR Phase II Award, September 2023

A STTR Phase II contract was awarded to GATEWAY BIOTECHNOLOGY, INC. in September, 2023 for $473,509.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/2504061
Is a
SBIR/STTR Awards
SBIR/STTR Awards
0

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
‌
GATEWAY BIOTECHNOLOGY, INC.
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
STTR0
Contract Number (US Government)
4R42AG078721-020
Award Phase
Phase II0
Award Amount (USD)
473,5090
Date Awarded
September 15, 2023
0
End Date
August 31, 2025
0
Abstract

Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. While this condition, called cochlear synaptopathy or hidden hearing loss, can be detected in animal models by a reduction of suprathreshold sound evoked wave-1 amplitude of auditory brainstem response (ABR) and confirmed by post-mortem quantitative histology, its diagnosis in humans remains challenging. Several non-invasive electrophysiological methods such as ABR and electrocochleography (ECochG) have been tested to detect human cochlear synaptopathy. Two major obstacles to their proposed application include: (1) a high variability of ABR/ECochG wave amplitudes, and (2) a lack of direct histological validation for living humans. My strategy here is to develop a new electrical device able to generate a calibration pulse to reduce high variability in ABR/ECochG wave metrics. The validation issue will be addressed by applying machine learning to identify multiple ABR/ECochG markers associated with cochlear synaptopathy first in animal models, in which cochlear synaptopathy can be directly validated by histologic synaptic counting, and then apply these identified features for human diagnosis. My hypothesis is that clinical diagnosis of human cochlear synaptopathy can be achieved by improving both hardware and software related to ABR/ECochG data collection and analysis. Based on our preliminary studies, we will continue to improve our electrical circuit to test if our calibration pulse device can address the variability issue, and at the same time, we will identify ABR/ECochG features associated with age-related cochlear synaptopathy in mice and then validate these identified features in gerbils since its hearing range is similar to humans. Finally, I will perform a longitudinal study to test identified features in humans during aging.Early detection of cochlear synaptopathy may lead to effective preventive strategies that would delay or potentially prevent further development of ARHL. Completion of this project is therefore expected to lead to a major shift in current clinical diagnosis of ARHL, while providing a unique training opportunity for the principal investigator to develop skills in developing commercial medical devices.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like GATEWAY BIOTECHNOLOGY, INC. STTR Phase II Award, September 2023

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.